Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
Retrieved on:
Monday, June 5, 2023
EASL, Pitango, Therapy, NASH, Norwest Venture Partners, Adi, Journal of Accounting and Economics, Clinical trial, CMMB, General partnership, Physiology, MBA, Biomarker, Certified Public Accountant, Doctor of Philosophy, Economics, Health care efficiency measures, Congress, TEL, Data analysis, MD, Patient, Investment, Biophysics, Fattal, Fatty liver disease, CFO, Knowledge, Growth, PSC, Systemic scleroderma, BA, Autoimmunity, Inflammation, Management, Pharmaceutical industry, Finance, Tel Aviv University, Accounting
(Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.
Key Points:
- (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.
- "I am excited to resume my corporate leadership responsibilities and look forward to continued engagement with our key stakeholders," said Dr. Mor.
- "This transition of executive leadership to the company's founding team will focus on maintaining business continuity and ensuring clinical plan execution," continued Dr. Mor.
- Adi's exceptional corporate leadership skills are complemented by her extensive knowledge in autoimmune, inflammatory and fibrotic diseases and broad experience in developing monoclonal antibodies.